Speakers at EmTech India 2011 spoke
about the innovations that are being undertaken by their organizations
and how these could be applied to business and strategy.
(L-R): Dr Sanjay Kakkar, trustee,
Thrombosis Research Institute, Bangalore; Dr Chetan Chitnis, principal
leader – Malaria Group, ICGEB, New Delhi; Prof D Balasubramanian,
director of research, LV Prasad Eye Institute, Hyderabad; Mr Udaykumar
Ranga, professor, JNCASR, Bangalore; and Mr Jeffrey M Karp,
assistant professor in Medicine at Harvard Medical School, US, took
part in a panel discussion on ‘Activating the Innovation Gene’ held as
part of EmTech 2011 in Bangalore, India, on March 22, 2011.
The EmTech India 2011 conference in its third edition in India saw
several eminent personalities shed light on the emerging trends and the
future of technology. The event, which is conducted every year by MIT's
Technology Review’s India edition by CyberMedia, Asia’s
leading technology publisher, was held during 22-23 March in Bangalore.
The plenary session on day one of the event saw several speakers
discuss the imperatives in the field of vaccine research. The speakers
included Dr Chetan Chitnis, principal leader, Malaria Group,
International Center for Genetic Engineering and Biotechnology (ICGEB),
Delhi; Professor Udaykumar Ranga, Professor, JNCASR, Bangalore; Dr
Sanjay Kakkar, Trustee, Thrombosis Research Institute, Bangalore and Dr
Jeffrey M. Karp, HST Affiliate Faculty, Assistant Professor in Medicine
at Harvard Medical School and Co-Director, Regenerative Therapeutics
Center, Brigham & Women’s Hospital. The session was moderated by Dr
D Balasubramanian, director of research, LV Prasad Eye Institute,
Hyderabad.
Dr Chitnis, while sharing his thoughts on the kind of innovation
happening on developing vaccine against malaria, said, “We are
developing a vaccine for P. vivax malaria based on PvRII. Methods to
produce recombinant PvRII have been developed and efforts to identify
an optimal adjuvant formulation are underway. Clinical grade P.
falciparum vaccine candidate JAIVAC-1 has been manufactured under cGMP
by an Indian biotechnology company, Bharat Biotech, Hyderabad.”
Government of India's Million Death Study revealed that about 205,000
Indians under age 70 die annually due to Malaria. On the other hand,
World Health Organization (WHO) reports put the figure at 15,000.
Also, the Indian population is at high risk of heart attacks when
compared with the population in the West because of many factors
including, life style changes and smoking among others. Considering the
increase in the number of people that are being diagnosed with
cardiovascular diseases, Bangalore based Thrombosis Research Institute,
has developed a DNA based saliva test to check the risk of heart
disease.
Speaking at the panel discussion, Dr Kakkar said, 'The genetic test has
been designed specifically for the indigenous population, using the
Western technology. After verification and known risks, preventive
measures for weight, adequate exercise and proper diet to reduce the
risk of such losses can be started.”
Professor Ranga, while speaking on developments made by the team at the
Molecular Biology and Genetics Unit, on developing HIV vaccine said,
“India can look at utilizing the expertise gained in traditional
medicine such as ayurveda, unani, siddha medicines over thousands of
years, in developing poly herbal medicine for HIV. ”
Meanwhile, Dr Karp, pointed out that commercialization will always
drive innovation.